Previous clinical studies showed that IFN-γ therapy has no impact on survival in patients with SCLC in remission after standard therapies [51, 52] and this finding may relate to the ability of IFN-γ to induce immune-resistance through the PD-L1/PD-1 pathway. This evidence concerns the gene IFNG and small cell lung carcinoma.